Antisense Oligonucleotides Directd against Human ICAM-I RNA.
Patent, Filed 12 Oct 93, patented 3 Dec 96,
DEPARTMENT OF THE NAVY WASHINGTON DC
Pagination or Media Count:
The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ICAM-I mRNA transcript using at least one oligonucleotide which is complementary to at least a portion of the human ICAM-I mRNA is disclosed, as are oligonucleotides which are complementary to portions of the ICAM-I mRNA and compositions comprising the oligonucleotides.
- Medicine and Medical Research
- Stress Physiology